GSA Capital Partners’s Phathom Pharmaceuticals PHAT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-15,173
| Closed | -$123K | – | 1985 |
|
|
2024
Q4 | $123K | Buy |
15,173
+90
| +0.6% | +$730 | 0.01% | 1498 |
|
|
2024
Q3 | $273K | Sell |
15,083
-14,323
| -49% | -$259K | 0.02% | 1267 |
|
|
2024
Q2 | $303K | Buy |
29,406
+15,232
| +107% | +$157K | 0.02% | 1277 |
|
|
2024
Q1 | $151K | Buy |
+14,174
| New | +$151K | 0.01% | 1446 |
|
|
2023
Q4 | – | Sell |
-121,892
| Closed | -$1.26M | – | 1820 |
|
|
2023
Q3 | $1.26M | Buy |
121,892
+67,983
| +126% | +$705K | 0.11% | 290 |
|
|
2023
Q2 | $772K | Buy |
53,909
+33,677
| +166% | +$482K | 0.08% | 456 |
|
|
2023
Q1 | $144K | Buy |
20,232
+1,715
| +9% | +$12.2K | 0.01% | 1312 |
|
|
2022
Q4 | $208K | Buy |
+18,517
| New | +$208K | 0.03% | 1160 |
|
|
2021
Q1 | – | Sell |
-21,871
| Closed | -$727K | – | 1392 |
|
|
2020
Q4 | $727K | Buy |
+21,871
| New | +$727K | 0.12% | 234 |
|